Background: Neutropenia and thrombocytopenia are wellrecognised complications of systemic chemotherapy. In cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), the interplay between surgical factors and systemic toxicity of chemotherapeutics must be considered when considering post-operative haematological outcomes. We sought to quantify the incidence of these events in cytoreductive surgery and HIPEC at our institution. Methods: We conducted a single centre, a retrospective cohort study of 50 consecutive patients who underwent cytoreductive surgery and HIPEC from 2002 to 2015. Routine haematological data were analysed and complications classified according to CTCAE 4.0. Subgroup analysis was undertaken to compare those who received or not perioperative systemic chemotherapy. Results: The rate of all-grade post-procedure neutropenia was 4 % (n = 2/50); one grade 1, and one grade 4 neutropenia. The patient with grade 4 neutropenia died day 57 post-operatively, despite subsequent growth factor support. Eight percent (n = 4/50) of patients had thrombocytopenia preoperatively. The overall rate of post-procedure thrombocytopenia was 46 % with grade 3-4 thrombocytopenia of 4 %. If not present preoperatively, thrombocytopenia onset was on day 1 or 2 post-operatively, with a median duration of 3 days.
Introduction
Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is a potentially curative intervention for pseudomyxoma peritoneii and some types of peritoneal carcinomatosis, including colorectal cancer and mesothelioma. This procedure involves complete surgical removal of all visible cancer deposits followed by the administration of HIPEC.
By administering chemotherapy directly to the peritoneal cavity, an increased dose of cytotoxic medications can be delivered to malignant cells with limited systemic absorption of the drug [1] [2] [3] [4] [5] .
Although neutropenia and thrombocytopenia are recognised complications of systemic chemotherapeutic administration, the reporting from trials of HIPEC varies in detail provided with regards to haematological outcomes. In CRS and HIPEC, the interplay between surgical factors and systemic toxicity of chemotherapeutics must be considered when considering post-operative haematological response.
After a mortality following significant neutropenia post CRS and HIPEC, we sought to quantify the incidence of neutropenia and thrombocytopenia post CRS and HIPEC at our institution.
Materials and methods

Study design
This was a single centre, retrospective cohort study from a prospectively maintained database of all patients who underwent CRS and HIPEC at a tertiary referral hospital in Adelaide, South Australia.
Patients who had CRS at our institution from first procedure, in 2002, until the end of 2015 were identified from our database. The maintenance of this database and research resulting from it was approved by the Central Adelaide Human Research Ethics Committee. Patients who had not undergone both CRS and HIPEC were excluded from analysis (e. g. incurable disease at time of operation).
Cytoreductive surgery and HIPEC
Selection criteria for CRS and HIPEC included peritoneal carcinomatosis without evidence of other metastatic disease and general fitness for surgery. CRS was undertaken as per Sugarbaker et al. [6] Laparotomy was performed, and peritoneum stripped from all surfaces macroscopically involved in the disease process. Cytoreduction sometimes required resection of bowel and removal of other organs, such as cholecystectomy, omentectomy or hysterectomy. Once cytoreduction was complete, a Coliseum technique was used for HIPEC at 42°C for 90 minutes.
Choice of chemotherapeutic agent was based on the primary pathology being treated, with consideration given to any prior chemotherapy received and the patient's response. In general terms, patients with pseudomyxoma peritoneii received mitomycin C (MMC) 12.5-15 mg/m 2 . Patients with mesothelioma received cisplatin 100 mg/m 2 . Patients with metastatic colorectal cancer received MMC 12.5-15 mg/m 2 or oxaliplatin 300-350 mg/m 2 .
From 2013, patients with metastatic colorectal cancer also received intravenous 5-fluorouracil (5-FU) bolus of 400 mg/m 2 and folinic acid 20 mg/m 2 administered at the time of HIPEC, at the discretion of the prescribing oncologist.
Audit of outcomes
A retrospective audit of haematological data was undertaken from preoperative period to day of discharge, or post-operative day 20, whichever occurred first. Day 20 was chosen as an endpoint as literature suggested that any haematological effects should be evident within the first 2 weeks post chemotherapy administration [3, 7] . Patient data were analysed in Microsoft Excel to identify magnitude and duration of neutropenia and thrombocytopenia. Haematological complications were graded using the CTCAE 4.0 classification [8] . Thrombocytopenia was defined as platelets < 150 × 10 9 /L. Neutropenia was defined as absolute neutrophil count (ANC) < 2.0 × 10 9 /L.
Results
Sixty two patients underwent CRS within the audit period, 12 patients did not receive HIPEC as their disease was deemed incurable at time of surgery. Fifty patients were thus eligible for inclusion. Table 1 summarises the patient and treatment characteristics. There were more females than males treated, with a median age of 64 years (range 22-80 years). The chemotherapy administered is also listed in Table 1 . From 2013 onwards, 16 patients received an intraoperative dose of 5-FU in addition to HIPEC.
The pathologies being treated were pseudomyxoma peritoneii (n = 30), metastatic adenocarcinoma (n = 10), peritoneal mesothelioma (n = 7), primary peritoneal carcinoma (n = 1) and metastatic adrenocortical carcinoma (n = 1). One patient had no residual malignancy identified.
Most patients mounted an inflammatory haematological response to their surgery, with thrombophilia and neutrophilia in the post-operative period. Two of fifty patients (4 %) experienced neutropenia post-operatively. One patient had grade 1 neutropenia (ANC = 1.72) day 4-5 post-operatively, after receiving MMC, but without IV 5-FU bolus. The other patient had grade 4 neutropenia (ANC = 0.31) day 8-12 post-operatively, after receiving oxaliplatin and IV 5-FU bolus. This patient was commenced on filgrastim. Ultimately, this patient died day 56 post-operatively from complications relating to intraabdominal sepsis despite resolution of neutropenia on post-operative day 13. Four of fifty patients (8 %) were thrombocytopenic preoperatively (range 87-141 × 10 9 /L). Forty-six percent (23/50) of patients had a thrombocytopenia in the postoperative period [ Table 2 ].
Excluding those with pre-existing thrombocytopenia, thrombocytopenia always developed on day 1 or 2 postoperatively ( Figure 1 ) but was generally of short duration with a median duration of 3 days. One patient had prolonged thrombocytopenia of 18 days; this was the same patient with a grade 4 neutropenia.
Those patients with preoperative thrombocytopenia also remained thrombocytopenic post-operatively, with a further drop in platelet count. None of these patients had grade 3 or 4 thrombocytopenia.
Subgroup analysis was undertaken to ascertain the effect, if any, of IV 5-FU bolus on haematological outcomes. Results are shown in Table 3 . Of the 50 patients, 16 received IV 5-FU, and of these, six were thrombocytopenic post-operatively. One of these six was also neutropenic. There was no significant difference in incidence of post-operative thrombocytopenia between patients that received IV 5-FU and those that did not (Chi-square 0.68, p = 0.41). Sample size was insufficient to investigate the effect of IV 5-FU bolus on neutropenia.
Discussion
The advantage of HIPEC over systemic chemotherapy for peritoneal malignancy is in achieving high local concentration of chemotherapeutic drug with limited systemic absorption. This is explained by the slow absorption of chemotherapeutic drugs from the peritoneal cavity, attributed to the existence of a 'peritoneal-plasma' barrier that limits systemic absorption of these drugs from the peritoneal cavity, despite cytoreductive surgery and high concentration gradients of drug between plasma and peritoneal cavity [4, 5] . The cytotoxic effect of the drug is augmented by hyperthermia.
Systemic toxicity, including haematological toxicity, does occur with HIPEC but is less common than with systemic administration of chemotherapy [5] . Moreover, neutrophil and platelet responses after CRS and HIPEC are a function of both the surgical intervention and chemotherapeutic effect [3, 7, 9] . Although delivered locally, we have shown HIPEC has the potential to cause clinically significant systemic toxicity.
Surgical stress promotes neutrophilia, whereas chemotherapeutic toxicity promotes neutropenia, in a dosedependent manner [3, 7] . In a model developed by Perez-Ruixo et al., neutrophil dynamics post HIPEC follow a 'signature pattern'; neutrophilia develops within 24 hours of surgery. Neutrophil count would be expected to be at its lowest approximately 7 days post-operatively, and should return to the normal range by day 15 post-operatively [7] . In our cohort, two patients (4 %) developed neutropenia. In one patient, who was treated with oxaliplatin and 5-FU bolus, this was clinically significant (grade 4), requiring filgrastim. This same patient also had prolonged thrombocytopenia, and ultimately died due to complications of sepsis. The two patients in our cohort who developed neutropenia received different chemotherapeutic agents; Table 2 : Incidence of post-operative thrombocytopenia.
Platelet range
Frequency, n Incidence, % one received oxaliplatin with 5-FU bolus, and the other MMC without 5-FU bolus. Our data does not have sufficient power to compare complication rates between different chemotherapeutic regimens. MMC is reported by some to have a higher rate of neutropenia than oxaliplatin [10] [11] [12] . However, in a matched-pair study by Glockzin et al., comparing a MMC and doxorubicin HIPEC protocol with an oxaliplatin protocol for CRS and HIPEC, they found no significant difference in perioperative mortality or morbidity between the two regimes, and did not have any patients develop haematological complications of grade 3-4 [13] .
Post-operative day of onset of thrombocytopenia
In a review of the literature, reported rates of neutropenia vary widely, from 'rarely experienced and thus not reported' to 78 % [1, 2, 12, 14] .
In a review by Newton et al. of factors contributing to morbidity and mortality in CRS and HIPEC, grade 4 neutropenia after HIPEC was associated with mortality of 66 % (n = 4/6) [15] . The rate of 4 % grade 3-4 neutropenia in this study is significantly less than that reported in most studies.
Thrombocytopenia post CRS and HIPEC similarly results from both surgical factors and potential myelosuppression due to systemic cytotoxic absorption [2, 9, 16] . Platelet consumption for haemostasis during and after surgical procedures also can lead to thrombocytopenia. Also, there are multiple mechanisms of chemotherapyinduced thrombocytopenia, with myelosuppression being the most common. Oxaliplatin also has the potential to cause thrombocytopenia due to other mechanisms, including immune thrombocytopenia [16] . MMC can induce thrombocytopenia as part of haemolytic ureamic syndrome, although this is generally dose dependent [17] . Rates of grade 3-4 post-operative thrombocytopenia are reported in other studies to be between 5.5 and 19.5 % [2, 9] compared to 4 % in this study. All-grade thrombocytopenia was seen day 1 or 2 post-operatively and in all but 1 patient was short lived with a median duration of 3 days [ Figure 1 ]. The short-lived nature of the thrombocytopenia suggests that significant toxicity was not present.
This initial audit of neutropenia and thrombocytopenia post CRS and HIPEC was a retrospective study, and some limitations result from that. Whilst most patients had daily blood tests, some did not, and this limits data resolution in our investigation. The authors feel this is unlikely to have resulted in missed neutropenia or thrombocytopenia, as haematological abnormalities would have prompted clinicians to perform more frequent blood tests. There are other confounding factors to this analysis that have not been accounted for, in particular, transfusion support during surgery. The sample size is also not sufficient to adequately consider the effect of different chemotherapeutic regimes on these outcomes. The non-standard nature of HIPEC protocols between centres means it is also difficult to speculate on the reasons for such variability in rates of neutropenia and thrombocytopenia in the literature. Lastly, we have not considered non-haematological complications in this study, and that may limit the ability to put these results in context of other centres.
These results serve to set a benchmark for the haematological outcomes from CRS and HIPEC at a single institution, and support further work in this area to assess factors that may help predict which patients are at risk of complications from this surgery. The significant event of grade 4 neutropenia serves to remind clinicians that systemic toxicity can occur in HIPEC with a high risk of mortality, despite its targeted local delivery.
